Literature DB >> 20631352

A role of the bile salt receptor FXR in atherosclerosis.

Jurre Hageman1, Hilde Herrema, Albert K Groen, Folkert Kuipers.   

Abstract

This study reviews current insights into the role of bile salts and bile salt receptors on the progression and regression of atherosclerosis. Bile salts have emerged as important modifiers of lipid and energy metabolism. At the molecular level, bile salts regulate lipid and energy homeostasis mainly via the bile salt receptors FXR and TGR5. Activation of FXR has been shown to improve plasma lipid profiles, whereas Fxr(-/-) mice have increased plasma triglyceride and very-low-density lipoprotein levels. Nevertheless, high-density lipoprotein cholesterol levels are increased in these mice, suggesting that FXR has both anti- and proatherosclerotic properties. Interestingly, there is increasing evidence for a role of FXR in "nonclassical" bile salt target tissues, eg, vasculature and macrophages. In these tissues, FXR has been shown to influence vascular tension and regulate the unloading of cholesterol from foam cells, respectively. Recent publications have provided insight into the antiinflammatory properties of FXR in atherosclerosis. Bile salt signaling via TGR5 might regulate energy homeostasis, which could serve as an attractive target to increase energy expenditure and weight loss. Interventions aiming to increase cholesterol turnover (eg, by bile salt sequestration) significantly improve plasma lipid profiles and diminish atherosclerosis in animal models. Bile salt metabolism and bile salt signaling pathways represent attractive therapeutic targets for the treatment of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631352     DOI: 10.1161/ATVBAHA.109.197897

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  32 in total

1.  Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia/reperfusion injury.

Authors:  Jun Pu; Ancai Yuan; Peiren Shan; Erhe Gao; Xiaoliang Wang; Yajing Wang; Wayne Bond Lau; Walter Koch; Xin-Liang Ma; Ben He
Journal:  Eur Heart J       Date:  2012-02-03       Impact factor: 29.983

2.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Authors:  Brent A Neuschwander-Tetri; Rohit Loomba; Arun J Sanyal; Joel E Lavine; Mark L Van Natta; Manal F Abdelmalek; Naga Chalasani; Srinivasan Dasarathy; Anna Mae Diehl; Bilal Hameed; Kris V Kowdley; Arthur McCullough; Norah Terrault; Jeanne M Clark; James Tonascia; Elizabeth M Brunt; David E Kleiner; Edward Doo
Journal:  Lancet       Date:  2014-11-07       Impact factor: 79.321

3.  Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptors.

Authors:  Nidhi Singh; Manisha Yadav; Abhishek Kumar Singh; Harish Kumar; Shailendra Kumar Dhar Dwivedi; Jay Sharan Mishra; Anagha Gurjar; Amit Manhas; Sharat Chandra; Prem Narayan Yadav; Kumaravelu Jagavelu; Mohammad Imran Siddiqi; Arun Kumar Trivedi; Naibedya Chattopadhyay; Sabyasachi Sanyal
Journal:  Mol Endocrinol       Date:  2014-03-05

4.  An estrogen receptor β-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors.

Authors:  Suriyan Ponnusamy; Quynh T Tran; Thirumagal Thiyagarajan; Duane D Miller; Dave Bridges; Ramesh Narayanan
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-16

5.  Direct methylation of FXR by Set7/9, a lysine methyltransferase, regulates the expression of FXR target genes.

Authors:  Natarajan Balasubramaniyan; Meena Ananthanarayanan; Frederick J Suchy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-02-16       Impact factor: 4.052

6.  Subclinical Atherosclerosis in Pediatric Liver Transplant Recipients: Carotid and Aorta Intima-Media Thickness and Their Predictors.

Authors:  Emily R Perito; Andrew Phelps; Tabitha Vase; Vickie A Feldstein; Robert H Lustig; Philip Rosenthal
Journal:  J Pediatr       Date:  2017-12-07       Impact factor: 4.406

7.  Aging and transplantation - a topic for biomedicine or bioethics?

Authors:  William J Hubbard; Nassrin Dashti
Journal:  Aging Dis       Date:  2011-02-22       Impact factor: 6.745

8.  Cholestasis-induced bile acid elevates estrogen level via farnesoid X receptor-mediated suppression of the estrogen sulfotransferase SULT1E1.

Authors:  Xijun Liu; Ruyi Xue; Caiting Yang; Jianxin Gu; She Chen; Si Zhang
Journal:  J Biol Chem       Date:  2018-06-21       Impact factor: 5.157

9.  Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice.

Authors:  Xiaoyan Zhang; Shizheng Huang; Min Gao; Jia Liu; Xiao Jia; Qifei Han; Senfeng Zheng; Yifei Miao; Shuo Li; Haoyu Weng; Xuan Xia; Shengnan Du; Wanfu Wu; Jan-Åke Gustafsson; Youfei Guan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-24       Impact factor: 11.205

10.  Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation.

Authors:  Brian J Bennett; Thomas Q de Aguiar Vallim; Zeneng Wang; Diana M Shih; Yonghong Meng; Jill Gregory; Hooman Allayee; Richard Lee; Mark Graham; Rosanne Crooke; Peter A Edwards; Stanley L Hazen; Aldons J Lusis
Journal:  Cell Metab       Date:  2013-01-08       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.